CDTX Cidara Therapeutics, Inc.

9.45
+0.2  (2.16%)
Previous Close 9.25
Open 9.20
Price To book 1.74
Market Cap 157.56M
Shares 16,673,000
Volume 52,705
Short Ratio 7.82
Av. Daily Volume 62,455

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 initiated June 2016. Data due 4Q 2017.
CD101 IV - STRIVE
Candidemia
Phase 2 completion of enrollment announced January 4, 2017. Data due 1Q 2017.
CD101 Topical - RADIANT
Vulvovaginal candidiasis (VVC)

Latest News

  1. Antimicrobials Working Group Announces New Leadership Team
  2. CIDARA THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
  3. Cidara Therapeutics Completes Enrollment in Phase 2 RADIANT Trial Evaluating Novel Antifungal CD101 Topical in Vulvovaginal Candidiasis
  4. Cidara Therapeutics Completes Enrollment in Phase 2 RADIANT Trial Evaluating Novel Antifungal CD101 Topical in Vulvovaginal Candidiasis
  5. Coverage initiated on Cidara Therapeutics by H.C. Wainwright
  6. Newly Published Data Reinforce Growing Body of Evidence Supporting Cidara Therapeutics’ Lead Antifungal CD101
  7. Hedge Funds Aren’t Crazy About Cidara Therapeutics Inc (CDTX) Anymore
  8. Cidara Therapeutics, Inc. :CDTX-US: Earnings Analysis: Q3, 2016 By the Numbers : November 29, 2016
  9. Cidara Therapeutics’ Presentations at ASH 2016 to Highlight Potential Role of Novel Antifungal CD101 in Patients with Hematologic Malignancies
  10. Is Cidara Therapeutics (CDTX) Stock a Solid Choice Right Now?
  11. CIDARA THERAPEUTICS, INC. Financials
  12. Cidara Provides Corporate Update and Reports Third Quarter 2016 Financial Results
  13. Cidara Provides Corporate Update and Reports Third Quarter 2016 Financial Results
  14. CIDARA THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report
  15. Cidara Therapeutics to Present Data on Novel Antifungal CD101 at the Global Joint Conference of ICHS and INFOCUS
  16. Cidara Therapeutics to Present at the Stifel 2016 Healthcare Conference
  17. Cidara Therapeutics and Square 1 Bank Announce $20 Million Credit Facility
  18. Cidara Therapeutics and Square 1 Bank Announce $20 Million Credit Facility
  19. Cidara Therapeutics Announces Data from Studies of Novel Antifungal CD101 to be Presented at ACCP and IDWeek Annual Meetings
  20. Cidara Therapeutics Announces Closing of Public Offering of Common Stock, Including Exercise of Underwriter’s Option to Purchase Additional Shares

SEC Filings

  1. 8-K - Current report 17515964
  2. SC 13G - Statement of acquisition of beneficial ownership by individuals 161990427
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 161988031
  4. 8-K - Current report 161987990
  5. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 161986766
  6. 424B5 - Prospectus [Rule 424(b)(5)] 161928096
  7. 8-K - Current report 161928051
  8. 424B5 - Prospectus [Rule 424(b)(5)] 161924974
  9. 8-K - Current report 161924948
  10. 8-K - Current report 161915800